

# Edyta SzaÅ,ek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4103342/publications.pdf>

Version: 2024-02-01

47  
papers

280  
citations

933447

10  
h-index

1125743

13  
g-index

50  
all docs

50  
docs citations

50  
times ranked

350  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Safety of a Vegan Diet During Pregnancy. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2021, 75, 417-425.	0.1	5
2	Tapentadol and tobacco smoking – a pharmacokinetic and pharmacodynamic study in patients after open abdominal hysterectomy – a pilot study. <i>Acta Poloniae Pharmaceutica</i> , 2021, 78, 755-759.	0.1	0
3	Pharmacokinetic Drug Interaction Study of Sorafenib and Morphine in Rats. <i>Pharmaceutics</i> , 2021, 13, 2172.	4.5	6
4	The Effects of Bariatric Surgery and Gastrectomy on the Absorption of Drugs, Vitamins, and Mineral Elements. <i>Pharmaceutics</i> , 2021, 13, 2111.	4.5	10
5	The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid. <i>Investigational New Drugs</i> , 2020, 38, 574-583.	2.6	13
6	The oxidation and hypoglycaemic effect of sorafenib in streptozotocin-induced diabetic rats. <i>Pharmacological Reports</i> , 2020, 72, 254-259.	3.3	5
7	Influence of obesity on pharmacokinetics and analgesic effect of ketoprofen administered intravenously to patients after laparoscopic cholecystectomy. <i>Pharmacological Reports</i> , 2020, 72, 763-768.	3.3	0
8	The Influence of Paracetamol on the Penetration of Sorafenib and Sorafenib N-Oxide Through the Blood–Brain Barrier in Rats. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 801-808.	1.6	6
9	In vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110530.	5.6	7
10	In vivo assessment of the drug interaction between sorafenib and paracetamol in rats. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1039-1048.	2.3	3
11	Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats. <i>Pharmaceutics</i> , 2020, 12, 600.	4.5	14
12	Analgesic efficacy and safety of tapentadol in comparison with oxycodone in patients after open abdominal hysterectomy.. <i>Acta Poloniae Pharmaceutica</i> , 2020, 77, 505-514.	0.1	0
13	Endocrine abnormalities induced by the antiviral drugs and frequency of their occurrence. <i>Polski Merkuriusz Lekarski</i> , 2020, 48, 209-214.	0.3	0
14	Influence of Obesity and Type 2 Diabetes Mellitus on the Pharmacokinetics of Tramadol After Single Oral Dose Administration. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 579-584.	1.6	10
15	The Influence of Diabetes Mellitus on Glucuronidation and Sulphation of Paracetamol in Patients with Febrile Neutropenia. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 289-294.	1.6	1
16	Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. <i>European Review for Medical and Pharmacological Sciences</i> , 2019, 23, 4044-4051.	0.7	1
17	PHARMACOKINETIC INTERACTION AFTER ORAL COADMINISTRATION OF CLARITHROMYCIN AND THE TYROSINE KINASE INHIBITOR LAPATINIB IN RATS. <i>Acta Poloniae Pharmaceutica</i> , 2019, 76, 645-651.	0.1	0
18	A pharmacokinetic study on lapatinib in type 2 diabetic rats. <i>Pharmacological Reports</i> , 2018, 70, 191-195.	3.3	4

#	ARTICLE	IF	CITATIONS
19	The concomitant use of lapatinib and paracetamol - the risk of interaction. <i>Investigational New Drugs</i> , 2018, 36, 819-827.	2.6	3
20	HPLC method for determination of moxifloxacin in plasma and its application in pharmacokinetic analysis. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2017, 40, 8-12.	1.0	13
21	The pharmacokinetics of oral ketoprofen in patients after gastric resection. <i>Pharmacological Reports</i> , 2017, 69, 296-299.	3.3	6
22	Pharmacokinetic drug-drug interaction between erlotinib and paracetamol: A potential risk for clinical practice. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 102, 55-62.	4.0	9
23	Formation Rate – Limited Pharmacokinetics of Biologically Active Epoxy Transformers of Prodrug Treosulfan. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 1790-1797.	3.3	11
24	Pharmacokinetics of paracetamol in patients with chronic pancreatitis. <i>Pharmacological Reports</i> , 2016, 68, 733-736.	3.3	15
25	The alteration of pharmacokinetics of erlotinib and OSI420 in type 1 diabetic rabbits. <i>Pharmacological Reports</i> , 2016, 68, 964-968.	3.3	3
26	An HPLC method for levofloxacin determination and its application in biomedical analysis. <i>Journal of Analytical Chemistry</i> , 2016, 71, 840-843.	0.9	18
27	The pharmacokinetic interaction between levofloxacin and sunitinib. <i>Pharmacological Reports</i> , 2015, 67, 542-544.	3.3	12
28	The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2015, 40, 163-170.	1.6	4
29	The pharmacokinetics of the effervescent vs. conventional tramadol/paracetamol fixed-dose combination tablet in patients after total gastric resection. <i>Pharmacological Reports</i> , 2014, 66, 159-164.	3.3	5
30	The pharmacokinetics and hypoglycaemic effect of sunitinib in the diabetic rabbits. <i>Pharmacological Reports</i> , 2014, 66, 892-896.	3.3	11
31	The problems of urinary tract infections with <i>Candida</i> spp. aetiology in women. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2014, 68, 1036-1039.	0.1	7
32	The penetration of sunitinib through the blood-brain barrier after the administration of ciprofloxacin. <i>Acta Poloniae Pharmaceutica</i> , 2014, 71, 691-7.	0.1	1
33	Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model. <i>Pharmacological Reports</i> , 2013, 65, 1383-1390.	3.3	7
34	Continuous Infusion of Antibiotics in Critically Ill Patients. <i>Current Clinical Pharmacology</i> , 2013, 8, 13-24.	0.6	13
35	The need to assay the real MIC when making the decision to eradicate <i>Staphylococcus aureus</i> with vancomycin. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2013, 67, 921-925.	0.1	6
36	Stability of calcium folinate (Teva) in concentrate after re-use and in dilute infusions in 0.9% NaCl in polyethylene bags. <i>Acta Poloniae Pharmaceutica</i> , 2013, 70, 301-7.	0.1	1

#	ARTICLE	IF	CITATIONS
37	Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. <i>Pharmacological Reports</i> , 2012, 64, 673-679.	3.3	3
38	Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. <i>Advances in Medical Sciences</i> , 2012, 57, 217-223.	2.1	10
39	Sunitinib in combination with clarithromycin or azithromycin – is there a risk of interaction or not?. <i>Pharmacological Reports</i> , 2012, 64, 1554-1559.	3.3	6
40	Comparison of the pharmacokinetics of paracetamol from two generic products in patients after total gastric resection. <i>Pharmacological Reports</i> , 2011, 63, 1518-1525.	3.3	6
41	The stability of fludarabine phosphate in concentrate and diluted with sodium chloride 0.9%. <i>Wspolczesna Onkologia</i> , 2011, 3, 142-146.	1.4	0
42	The PK/PD index (C <sub>MAX</sub> /MIC) for ciprofloxacin in patients with cystic fibrosis. <i>Acta Poloniae Pharmaceutica</i> , 2011, 68, 777-83.	0.1	9
43	Analysis of pharmacokinetics and PK/PD parameter C <sub>max</sub> /MIC for ciprofloxacin in patients with neutropenic fever. <i>Wspolczesna Onkologia</i> , 2010, 4, 286-290.	1.4	0
44	Bioequivalence Study of Two Losartan Formulations Administered Orally in Healthy Male Volunteers. <i>Arzneimittelforschung</i> , 2006, 56, 723-728.	0.4	4
45	Comparative Bioavailability Study of Two Preparations of Letrozole in Healthy Subjects. <i>Arzneimittelforschung</i> , 2005, 55, 514-519.	0.4	3
46	Bioavailability Study of Drotaverine from Capsule and Tablet Preparations in Healthy Volunteers. <i>Arzneimittelforschung</i> , 2004, 54, 298-302.	0.4	6
47	Pharmaceutical availability of betamethasone dipropionate and gentamicin sulfate from cream and ointment. <i>Acta Poloniae Pharmaceutica</i> , 2002, 59, 99-103.	0.1	2